Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome

BACKGROUND: Atypical hemolytic uremic syndrome (HUS) is associated with high recurrence rates after kidney transplant, with devastating outcomes. In late 2011, experts in France recommended the use of highly individualized complement blockade–based prophylaxis with eculizumab to prevent post-transpl...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Am Soc Nephrol
Main Authors: Zuber, Julien, Frimat, Marie, Caillard, Sophie, Kamar, Nassim, Gatault, Philippe, Petitprez, Florent, Couzi, Lionel, Jourde-Chiche, Noemie, Chatelet, Valérie, Gaisne, Raphael, Bertrand, Dominique, Bamoulid, Jamal, Louis, Magali, Sberro Soussan, Rebecca, Navarro, David, Westeel, Pierre-Francois, Frimat, Luc, Colosio, Charlotte, Thierry, Antoine, Rivalan, Joseph, Albano, Laetitia, Arzouk, Nadia, Cornec-Le Gall, Emilie, Claisse, Guillaume, Elias, Michelle, El Karoui, Khalil, Chauvet, Sophie, Coindre, Jean-Philippe, Rerolle, Jean-Philippe, Tricot, Leila, Sayegh, Johnny, Garrouste, Cyril, Charasse, Christophe, Delmas, Yahsou, Massy, Ziad, Hourmant, Maryvonne, Servais, Aude, Loirat, Chantal, Fakhouri, Fadi, Pouteil-Noble, Claire, Peraldi, Marie-Noelle, Legendre, Christophe, Rondeau, Eric, Le Quintrec, Moglie, Frémeaux-Bacchi, Véronique
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Nephrology 2019
נושאים:
Clinical Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6900783/
https://ncbi.nlm.nih.gov/pubmed/31575699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2019040331
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים